The ERCC1 C118T Polymorphism Predicts Clinical Outcomes of Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Meta-analysis Based on 22 Studies
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The ERCC1 C118T Polymorphism Predicts Clinical Outcomes of Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Meta-analysis Based on 22 Studies
Authors
Keywords
-
Journal
Asian Pacific Journal of Cancer Prevention
Volume 15, Issue 19, Pages 8383-8390
Publisher
Asian Pacific Organization for Cancer Prevention
Online
2014-12-19
DOI
10.7314/apjcp.2014.15.19.8383
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population
- (2013) Hui-Yan Li et al. Asian Pacific Journal of Cancer Prevention
- DNA Repair Gene Associated with Clinical Outcome of Epithelial Ovarian Cancer Treated with Platinum-based Chemotherapy
- (2013) Shan Kang et al. Asian Pacific Journal of Cancer Prevention
- Associations of ABCB1 and XPC Genetic Polymorphisms with Susceptibility to Colorectal Cancer and Therapeutic Prognosis in a Chinese Population
- (2013) Ai-Min Yue et al. Asian Pacific Journal of Cancer Prevention
- Effect of Variation of ABCB1 and ABCC3 Genotypes on the Survival of Bone Tumor Cases after Chemotherapy
- (2013) Jie Yang et al. Asian Pacific Journal of Cancer Prevention
- Single Nucleotide Polymorphisms in the NER Pathway and Clinical Outcome of Patients with Bone Malignant Tumor
- (2013) Xiao-Hui Sun et al. Asian Pacific Journal of Cancer Prevention
- Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer
- (2013) Kyung-Hun Lee et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
- (2013) Lucía Cortejoso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer
- (2013) Tomoyo Oguri et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
- (2013) T. Nishina et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Predictive Role of ERCC1 and XPD Genetic Polymorphisms in Survival of Chinese Non-small Cell Lung Cancer Patients Receiving Chemotherapy
- (2012) Zhen-Yong Zhang et al. Asian Pacific Journal of Cancer Prevention
- Cancer treatment and survivorship statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pharmacogenetics of Oxaliplatin as Adjuvant Treatment in Colon Carcinoma
- (2012) Arantza Fariña Sarasqueta et al. Molecular Diagnosis & Therapy
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis
- (2011) Ming Yin et al. CLINICAL CANCER RESEARCH
- Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes
- (2011) M. Inada et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer
- (2011) Jian Cheng et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Use of a comprehensive panel of biomarkers to predict response to a fluorouracil–oxaliplatin regimen in patients with metastatic colorectal cancer
- (2011) Maria J Lamas et al. PHARMACOGENOMICS
- Platinum-DNA Interactions and Subsequent Cellular Processes Controlling Sensitivity to Anticancer Platinum Complexes
- (2010) Saeed Ahmad CHEMISTRY & BIODIVERSITY
- Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
- (2010) Valérie Boige et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy
- (2010) Ming-Yii Huang et al. Pharmacogenetics and Genomics
- EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer
- (2009) K.-L. G. Spindler et al. ANNALS OF ONCOLOGY
- Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
- (2009) W Chua et al. BRITISH JOURNAL OF CANCER
- The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer
- (2009) Jun Liang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Influence ofGSTP1I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma
- (2009) Yen-Chung Chen et al. CANCER SCIENCE
- Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
- (2008) L Paré et al. BRITISH JOURNAL OF CANCER
- ERCC1codon 118 C→T polymorphism associated withERCC1expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma
- (2008) Peter Mu-Hsin Chang et al. CANCER SCIENCE
- A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients
- (2008) A. Woelfelschneider et al. CARCINOGENESIS
- Platinum Resistance: The Role of DNA Repair Pathways
- (2008) L. P. Martin et al. CLINICAL CANCER RESEARCH
- Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
- (2008) Eva Martinez-Balibrea et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of Weekly Intravenous Oxaliplatin Combined With Oral Daily Capecitabine and Radiotherapy With Biologic Correlates in Neoadjuvant Treatment of Rectal Adenocarcinoma
- (2008) Marwan G. Fakih et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
- (2008) Jim Cassidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial
- (2008) Michael S. Braun et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More